↓ Skip to main content

Colistin for lung infection: an update

Overview of attention for article published in Journal of Intensive Care, January 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)

Mentioned by

twitter
12 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
122 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Colistin for lung infection: an update
Published in
Journal of Intensive Care, January 2015
DOI 10.1186/s40560-015-0072-9
Pubmed ID
Authors

Mohan Gurjar

Abstract

Increasing incidence of resistance of gram-negative bacteria against even newer antibiotic including carbapenem has generated interest in the old antibiotic colistin, which are being used as salvage therapy in the treatment of multidrug resistant infection. Colistin has excellent bactericidal activity against most gram-negative bacilli. It has shown persist level in the liver, kidney, heart, and muscle; while it is poorly distributed to the bones, cerebrospinal fluid, lung parenchyma, and pleural cavity. Being an old drug, colistin was never gone through the drug development process needed for compliance with competent regulatory authorities that resulted in very much limited understanding of pharmacokinetic (PK) and pharmacodynamic (PD) parameters, such as C max/MIC ratio, AUC/MIC and T > MIC that could predict the efficacy of colistin. In available PK/PD studies of colistin, mean maximum serum concentration (C max) of colistin were found just above the MIC breakpoint at steady states that would most probably lead to suboptimal for killing the bacteria, even at dosages of 3.0 million international units (MIU) i.e., 240 mg of colistimethate sodium (CMS) intravenously every 8 h. These finding stresses to use high loading as well as high maintenance dose of intravenous colistin. It is not only suboptimal plasma concentration of colistin but also poor lung tissue concentration, which has been demonstrated in recent studies, poses major concern in using intravenous colistin. Combination therapy mainly with carbapenems shows synergistic effect. In recent studies, inhaled colistin has been found promising in treatment of lung infection due to MDR gram-negative bacteria. New evidence shows less toxicity than previously reported.

Twitter Demographics

The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 122 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 <1%
Ecuador 1 <1%
Italy 1 <1%
Unknown 119 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 17 14%
Student > Master 17 14%
Student > Postgraduate 16 13%
Researcher 12 10%
Student > Doctoral Student 12 10%
Other 36 30%
Unknown 12 10%
Readers by discipline Count As %
Medicine and Dentistry 47 39%
Agricultural and Biological Sciences 16 13%
Immunology and Microbiology 15 12%
Pharmacology, Toxicology and Pharmaceutical Science 13 11%
Biochemistry, Genetics and Molecular Biology 7 6%
Other 5 4%
Unknown 19 16%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 May 2020.
All research outputs
#3,529,725
of 15,168,956 outputs
Outputs from Journal of Intensive Care
#128
of 351 outputs
Outputs of similar age
#49,208
of 217,474 outputs
Outputs of similar age from Journal of Intensive Care
#1
of 1 outputs
Altmetric has tracked 15,168,956 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 351 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 217,474 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them